Filing Flows › Castle Biosciences (CSTL) › Q3 2025
Castle Biosciences (CSTL) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 3, 2025
Castle Biosciences (CSTL) reported revenue of $83.0M for the third quarter 2025 (Q3 2025), -3% from a year earlier and -4% from the quarter before. Operating margin was -8.2%, net loss $501K (0.6% of revenue).
Castle Biosciences, Q3 2025: revenue $83.0M (-3% year over year), operating margin -8.2%, net loss $501K, operating cash flow $22.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.0M | -4% | -3% |
| Operating profit | −$6.8M | — | — |
| Net earnings | −$501K | -111% | — |
| Operating cash flow | $22.6M | +9% | -3% |
| Free cash flow | $7.8M | -33% | -54% |
What changed
Revenue was $83.0M in Q3 2025, down 3% year over year and down 4% from the previous quarter. Dermatologic was the largest line at 58% of revenue. Dermatologic lost $16.5M year over year (down 25%), 604% of the total change.
Operating costs exceeded revenue by $6.8M, an operating margin of -8.2%. Total costs grew 11% against a revenue fall of 3%. The fastest-growing cost line was Cost of revenue (+20%). The quarter ended with a net loss of $501K, after a profit of $4.5M the previous quarter. Non-operating items added $6.4M, -1663% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $22.6M (down 3% year over year). Non-cash charges added back $3.8M of depreciation and amortization and $12.1M of share-based compensation. Working capital and other items added $7.2M. Capital expenditures of $14.8M left free cash flow of $7.8M.
Questions
What was Castle Biosciences' revenue in the third quarter 2025?
Castle Biosciences (CSTL) reported revenue of $83.0M for the third quarter 2025 (Q3 2025), -3% from a year earlier and -4% from the quarter before.
Was Castle Biosciences profitable in the third quarter 2025?
Operating loss was $6.8M (-8.2% of revenue) and net loss $501K.
Source: Castle Biosciences 10-Q on SEC EDGAR.